was read the article
array:24 [ "pii" => "S0001731024000243" "issn" => "00017310" "doi" => "10.1016/j.ad.2024.01.009" "estado" => "S300" "fechaPublicacion" => "2024-03-01" "aid" => "3788" "copyright" => "AEDV" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Dermosifiliogr. 2024;115:T265-T279" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0001731023008426" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.10.011" "estado" => "S300" "fechaPublicacion" => "2024-03-01" "aid" => "3701" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Dermosifiliogr. 2024;115:280-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Dispositivos médicos en pacientes diabéticos y dermatitis de contacto" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "280" "paginaFinal" => "287" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Medical Devices in Patients With Diabetes and Contact Dermatitis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0025" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 1106 "Tamanyo" => 64800 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.P. Velasco-Amador, Á. Prados-Carmona, F.J. Navarro-Triviño" "autores" => array:3 [ 0 => array:2 [ "nombre" => "J.P." "apellidos" => "Velasco-Amador" ] 1 => array:2 [ "nombre" => "Á." "apellidos" => "Prados-Carmona" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "Navarro-Triviño" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0025"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023008426?idApp=UINPBA000044" "url" => "/00017310/0000011500000003/v1_202403090527/S0001731023008426/v1_202403090527/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731023007329" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.09.005" "estado" => "S300" "fechaPublicacion" => "2024-03-01" "aid" => "3649" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Dermosifiliogr. 2024;115:265-79" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Roflumilast tópico y oral en dermatología. Una revisión narrativa" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "265" "paginaFinal" => "279" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Topical and Oral Roflumilast in Dermatology: A Narrative Review" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 823 "Tamanyo" => 93376 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Mansilla-Polo, E. Gimeno, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Mansilla-Polo" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Gimeno" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023007329?idApp=UINPBA000044" "url" => "/00017310/0000011500000003/v1_202403090527/S0001731023007329/v1_202403090527/es/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0001731023007329" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.09.005" "estado" => "S300" "fechaPublicacion" => "2024-03-01" "aid" => "3649" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Dermosifiliogr. 2024;115:265-79" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Roflumilast tópico y oral en dermatología. Una revisión narrativa" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "265" "paginaFinal" => "279" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Topical and Oral Roflumilast in Dermatology: A Narrative Review" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 823 "Tamanyo" => 93376 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Mansilla-Polo, E. Gimeno, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Mansilla-Polo" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Gimeno" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023007329?idApp=UINPBA000044" "url" => "/00017310/0000011500000003/v1_202403090527/S0001731023007329/v1_202403090527/es/main.assets" ] ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T265" "paginaFinal" => "T279" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Mansilla-Polo, E. Gimeno, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:3 [ "nombre" => "M." "apellidos" => "Mansilla-Polo" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "Gimeno" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:4 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" "email" => array:1 [ 0 => "morgadodaniel8@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Figueres, Girona, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Roflumilast tópico y oral en dermatología. Una revisión narrativa" ] ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 824 "Tamanyo" => 91465 ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The arrival of biologic drugs and small molecules has revolutionized the management of multiple inflammatory dermatoses such as psoriasis, atopic dermatitis, hidradenitis suppurativa, and alopecia areata, among others. However, their high cost poses a significant limitation, especially when used off-label.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Apremilast is an oral inhibitor of the enzyme phosphodiesterase-4 (PDE4), with immunomodulatory effects and no immunosuppression. It has been approved by the U.S. Food and Drug Administration (FDA) for the management of psoriasis,<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">2</span></a> psoriatic arthritis, and oral ulcers in patients with Behçet's disease.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> Its safety profile is just excellent and has been successfully used off-label to treat multiple dermatoses.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> Crisaborole is a topical PDE4 inhibitor approved to treat atopic dermatitis.<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">4</span></a> Roflumilast is another PDE4 inhibitor (PDE4i). Its oral form was initially approved by the European Medicines Agency (EMA) and the FDA to reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD) and chronic bronchitis phenotype.<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">5</span></a> Topical roflumilast cream at 0.3% was approved by the FDA in 2022 to treat of plaque psoriasis in patients older than 12 years, making it the first topical PDE4 inhibitor to be approved for the management of plaque psoriasis.<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">6</span></a> Back in April 2023, the FDA approved its topical use at 0.3% to treat seborrheic dermatitis.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">7</span></a> Thanks to its excellent safety profile, ease of dosing, and low cost (the price of oral roflumilast is around €35/month in Spain), this drug has been used orally to treat plaque psoriasis, recurrent oral aphthosis, hidradenitis suppurativa, nummular eczema, and lichen planus, among other dermatoses. Its potential uses are not only limited to the dermatology setting, but also extend to cognitive impairment, dementia, schizophrenia, and other neurological or psychiatric conditions,<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">8–13</span></a> ulcerative colitis, diabetes mellitus, obesity, polycystic ovary syndrome, asthma, bronchiectasis, and cystic fibrosis<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">14–19</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0005">table 1</a>). In this article, we’ll go over the mechanism of action, pharmacokinetics, long-term safety profile, and especially off-label uses of roflumilast in dermatology. We’ll also discuss diseases that could potentially benefit from this drug due to its similar mechanism of action compred to apremilast.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Material and methods</span><p id="par0015" class="elsevierStylePara elsevierViewall">We conducted a narrative review of the scientific medical literature currently available. Searches were performed on Medline and Google Scholar in the months of May and June 2023 using the following keyterms: “roflumilast,” “dermatology,” “skin,” “off-label,” “safety,” “apremilast,” “phosphodiesterase,” “phosphodiesterase 4,” “psoriasis,” “atopy,” “atopic dermatitis,” “eczema,” “hand eczema,” “nummular eczema,” “ulcers,” “oral ulcers,” “aphthous stomatitis,” “oral aphthosis,” “lichen planus,” “seborrheic dermatitis,” “hidradenitis,” “hidradenitis suppurativa,” “vitiligo,” “alopecia areata,” “sarcoidosis,” “Behçet's,” and “morphea.” This search was conducted among articles both written in Spanish and English. These articles were screened based on their abstracts, and selected according to their relevance after reading the studies. Similarly, a search with the keyterm “roflumilast” was conducted on clinicaltrials.gov. Two authors (MMP, and DMC) performed the search and article selection.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Roflumilast pharmacokinetics and mechanism of action</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Pharmacokinetics (<a class="elsevierStyleCrossRef" href="#tbl0010">table 2</a>)</span><p id="par0020" class="elsevierStylePara elsevierViewall">When administered orally, roflumilast is completely absorbed by the GI tract, and its bioavailability stands at nearly 80%, reching its maximum plasma concentration within 1 hour after its administration.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">20</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0010">table 2</a>). Regarding its metabolism, roflumilast is mainly hepatically metabolized by cytochromes CYP1A2 and CYP3A4, which turn the initial compound into the active metabolite roflumilast N-oxide (<a class="elsevierStyleCrossRef" href="#fig0005">figure 1</a><a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">21</span></a>), whih is ><span class="elsevierStyleHsp" style=""></span>90% of roflumilast overall PDE4 inhibitory activity.<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">22</span></a> The original and active metabolites of roflumilast mainly bind to plasma proteins (≥ 97%), and have a high volume of distribution, which is indicative of significant tissue penetration. No dose titration is required for geriatric age, or in cases of kidney disease. The clinical data available on roflumilast in patients with class A mild liver failure according to the Child-Pugh scale are not enough to recommend dose titration. Therefore, roflumilast should be used with caution in these individuals, and is contraindicated in moderate or severe liver failure.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">23</span></a> Roflumilast N-oxide is nearly 10 times more active than the original drug. The plasma half-life of roflumilast and its active metabolite is 17 to 30<span class="elsevierStyleHsp" style=""></span>hours, respectively.<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">24</span></a> Its excretion is mostly renal. While its pharmacokinetics is not affected by food intake, it could be affected by drugs that inhibit or induce CYP1A2 and CYP3A4, such as erythromycin, fluconazole, clarithromycin, or rifampicin.<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">25,26</span></a> Contraception is advised in fertile women, avoiding contraceptives with gestodene and ethinylestradiol due to shared metabolism.<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">25,26</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">The pharmacokinetics of 0.3% topical roflumilast cream is similar to that of oral roflumilast, taking into consideration the possibility of systemic absorption. Topically, its bioavailability is nearly 1.5%. After applying 3-to-6.5 grams/day for 15 days, it showed a mean exposure of 72.7 ± 53.1 and 628 ± 648<span class="elsevierStyleHsp" style=""></span>hours ng/mL.<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">7,27</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Mechanism of action and pharmacodynamics</span><p id="par0030" class="elsevierStylePara elsevierViewall">The exact mechanism of action of roflumilast is still to be elucidated (<a class="elsevierStyleCrossRef" href="#fig0010">figure 2</a>). Roflumilast and its active metabolite, roflumilast N-oxide, are PDE4 inhibitors (PDE4i), which happen to be the main enzymes involved in the metabolism of cyclic adenosine monophosphate (cAMP) found in lung tissue, skin, heart, kidneys, GI tract, and nervous system.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">28</span></a> At cellular level, PDE4 turns cAMP into adenosine monophosphate (AMP), thereby terminating the cellular messaging started by cAMP.<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">29</span></a> Roflumilast blocks the effect of PDE4, thus leading to the accumulation of cAMP in target cells, and increasing the signaling mediated by this molecule. This results in the inhibition of chemotaxis, reduction of inflammatory infiltration, decreased release of inflammatory and cytotoxic mediators, and an overal reduction of inflammation.<a class="elsevierStyleCrossRef" href="#bib0580"><span class="elsevierStyleSup">30</span></a> In dermatology, PDE4 is present in epidermal keratinocytes, neutrophils, Langerhans cells, and T lymphocytes.<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">31</span></a> Additionally, high levels of PDE4 have been found in peripheral blood mononuclear cells of patients with psoriasis, along with changes to ATP signaling.<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">32</span></a> The effectiveness of roflumilast is based on the inhibition of multiple inflammatory pathways, acting at epidermal level in keratinocytes and Langerhans cells, and dermal level in neutrophils, T lymphocytes, and macrophages.<a class="elsevierStyleCrossRefs" href="#bib0580"><span class="elsevierStyleSup">30,33</span></a> In atopic dermatitis, the hyperactivation of PDE4 induces an inflammatory response with polarization towards the Th2 pathway.<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">31,33</span></a> Specifically, cAMP has immunosuppressive and anti-inflammatory properties, which are mostly mediated by the nuclear factor-κB, which is key for the activity of multiple cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukins (IL) 1, 2, 8, 12, 18, 23, 27, or 36.<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">34,35</span></a> The multiple PDE4-mediate signaling pathways suggest that its blockade may be useful to trest various dermatoses, such as hidradenitis suppurativa, recurrent aphthous stomatitis, or lichen planus.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a></p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Safety profile</span><p id="par0035" class="elsevierStylePara elsevierViewall">Overall, roflumilast is well-tolerated and has an excellent safety profile<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">24</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0015">table 3</a>). In clinical trials (CT) on roflumilast to treat COPD and chronic bronchitis, the most common adverse event (AE) reported were diarrhea (8% to 9%), weight loss (6% to 12%), and nausea (5%). The incidence of nasopharyngitis (5% to 8%) and upper respiratory tract infections (4%) has been reported. However, these data are similar to those from the placebo group. AEs were mainly reported within the first weeks of treatment and were mostly self-limiting.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">28</span></a> A meta-analysis reported a higher rate of AEs in the roflumilast 500<span class="elsevierStyleHsp" style=""></span>μg/day group vs placebo.<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">36</span></a> A total of 15% discontinued treatment due to AEs (compared to 9% from the placebo group). The most common reasons for drug discontinuation were diarrhea and nausea.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">28</span></a> These initial analyses also reported higher rates of acute pancreatitis, psychiatric symptoms, and even prostate, lung, and colorectal cancer.<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">37</span></a> However, these initial findings could not be confirmed later, and roflumilast has even been proposed as an adjuvant therapy to treat various neoplasms, such as lung cancer or diffuse large B-cell lymphoma.<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">38,39</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Regarding weight loss, its incidence was nearly double (67.4% vs 37.7%) in the roflumilast group, and weight loss turned out to be significant (> 10% compared to baseline in 7.1% of the treatment group vs 1.9% of the control group).<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">37</span></a> This significant weight loss was associated with an improved glycemic metabolic profile and constitutes a potential therapeutic approach for the management of obesity, insulin resistance, and metabolic syndrome.<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">40,41</span></a> The psychiatric symptoms included in the initial studies were anxiety, depression, and insomnia.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">28</span></a> However, subsequent studies have confirmed that this risk is minimal, and in fact, roflumilast could be a promising drug to treat cognitive impairment, Alzheimer's disease, or schizophrenia.<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">8,10,42</span></a> Finally, the increased incidence of atrial fibrillation in patients on oral roflumilast has been a matter of discussion due to its higher incidence rate in the oral roflumilast group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>24) compared to the placebo group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9) in pre-commercialization trials. However, this has not been confirmed in the routine clinical practice. Additionally, the results of 24-hour Holter EKG monitoring in 55 patients showed no inter-gropu differences regarding heart rate or the occurrence of arrhythmias.<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">43</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Long-term safety data with PDE4i, specifically roflumilast, are equally favorable, with no new AEs or cumulative AEs being reported.<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">44,45</span></a> AEs have not been described either in diseases in which this drug is commonly used, such as COPD.<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">46</span></a> Currently, there is an ongoing clinical trial to assess the long-term safety profile of oral roflumilast to treat COPD.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">47</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The safety profile of topical roflumilast cream is also favorable, with exceptionally rare serious AE being reported due to its minimal absorption (bioavailability of 1% to 2%). The most common AEs reported include diarrhea (3% to 4%) and headache (2% to 4%), followed by insomnia, nausea, itching, or discomfort at the application site.<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">7,27</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Approved indications in dermatology</span><p id="par0055" class="elsevierStylePara elsevierViewall">The use of oral roflumilast has been approved by the FDA (unlike the EMA) for the topical treatment of plaque psoriasis and mild-to-moderate seborrheic dermatitis.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">6,7,27</span></a> The first report on roflumilast in the management of plaque psoriasis dates back to 2017 when Michels et al.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">48</span></a> described a case of psoriasis and concomitant COPD in which skin lesions improved while lung disease was being treated with oral roflumilast. In 2020, Papp et al.<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">49</span></a> reported the first stage I/IIa clinical trial (CT). This trial confirmed that a response was achieved when plaque psoriasis was treated with 0.5% and 0.15% topical roflumilast cream, which was superior compared to the administration of placebo. The DERMIS-1 and DERMIS-2 trials<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">27</span></a> led to the FDA approval of 0.3% topical roflumilast to treat plaque psoriasis, with 42.4% of cases achieving the Investigator's Global Assessment Scale (IGA) endpoint of complete clearance or improved IGA ≥ 2 points compared to baseline vs 6.1% of the patients from the control group (DERMIS-1), and 37.5% achieving the IGA endpoint compared to 6.9% from the control group (DERMIS-2). The safety profile was favorable in both studies, being GI discomfort the most common AE of all.<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">77</span></a> Recently, 2 stage IIb<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">50</span></a> and stage III<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">6</span></a> trials have been published confirming the efficacy profile of 0.3% topical roflumilast to treat pruritus, nocturnal rest, and scalp involvement, respectively (<a class="elsevierStyleCrossRef" href="#tbl0020">table 4</a>).</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">The FDA approval of topical roflumilast to treat seborrheic dermatitis was granted back in April 2023, following the publication of the results from a multicenter, placebo-controlled stage IIa CT on the efficacy and safety profile of 0.3% roflumilast in 226 patients with a ><span class="elsevierStyleHsp" style=""></span>3-month history of seborrheic dermatitis and IGA scores ≥ 3 (≥ moderate) with involvement of <<span class="elsevierStyleHsp" style=""></span>20% of the body surface area, including the scalp, face, trunk, and intertriginous areas.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">7</span></a> The trial achieved the target IGA (≥ 2-point clearance from baseline) in 73.8% of the patients on roflumilast, compared to 40.9% of the patients from the control group (<span class="elsevierStyleItalic">P</span> <<span class="elsevierStyleHsp" style=""></span>.001). The difference was significant from the 2<span class="elsevierStyleSup">nd</span> week of treatment. No higher rate of AEs was ever reported in the roflumilast group compared to the control one.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Off-label use of roflumilast in dermatology</span><p id="par0065" class="elsevierStylePara elsevierViewall">The medical literature available includes various trials (most of them small series of cases or initial CT) on the off-label use of roflumilast in dermatology (<a class="elsevierStyleCrossRef" href="#tbl0025">table 5</a>). Specifically, we found 4 clinical trials on the use of topical roflumilast. Regarding atopic dermatitis, one stage IIa CT (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>40) failed to achieve its proposed endpoints with 0.5% topical roflumilast being compared to placebo at 16 weeks. The primary endpoint of this trial was to determine the number of patients who achieved a reduction of, at least, 75% in the Hand Eczema Severity Index (HECSI75) after treatment with roflumilast topical cream.<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">51</span></a> Another randomized stage IIa clinical trial (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>136) showed an improved Eczema Area and Severity Index (EASI) score at 12 weeks with 0.15% topical roflumilast (superior to that obtained with the 0.05% concentration and placebo). However, these results did not reach statistical significance.<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">52</span></a> Two currently ongoing clinical trials on the effects of topical roflumilast to treat chronic hand eczema,<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">53</span></a> and papulopustular rosacea.<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">54</span></a> The CT on chronic hand eczema (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>230) is stage IIa trial on the efficacy and safety profile of topical roflumilast cream at 0.3% vs 0.1% vs placebo. The trial will be assessed at week 12. The CT on papulopustular rosacea (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>40) has already been completed and is currently pending publication. It evaluates the efficacy profile of 0.5% topical roflumilast vs placebo. Recently, a preclinical trial found higher levels of PDE4 in the skin of patients with vitiligo. After the application of topical roflumilast, the PDE4 levels dropped, and skin lesions improved partially.<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">55</span></a></p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">Regarding the off-label use of oral roflumilast, we found 4 trials on the off-labe use of roflumilast to treat psoriasis (<a class="elsevierStyleCrossRef" href="#tbl0025">table 5</a>). Gyldenløve et al. have recently reported the efficacy of 500<span class="elsevierStyleHsp" style=""></span>μg/day of oral roflumilast to treat plaque psoriasis in a stage III CT (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>46) vs placebo, with 35% of the intervention group achieving PASI 75 vs 13% of the placebo group (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.014) at week 12. Mostly mild AEs were reported.<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">45</span></a> Recently, the same group published the results of oral roflumilast in the first patient with refractory plaque psoriasis in whom this drug was ever prescribed, a 48-year-old man.<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">56</span></a> They later reported on the long-term disease progression (18 months) of this individual.<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">57</span></a> Recently, its utility has also been described in another clinical case: a 59-year-old man who was simultaneously being treated for COPD and psoriasis.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">48</span></a> In both cases, roflumilast was used at a dose of 500<span class="elsevierStyleHsp" style=""></span>μg/day, with no significant adverse events being reported. Aside from psoriasis, the scientific medical literature currently available includes 5 articles on oral roflumilast in dermatological disease (<a class="elsevierStyleCrossRef" href="#tbl0025">table 5</a>): 1 case series and 4 isolated clinical cases, most of them reported by the same health care center in Denmark. Ring et al. described 1 case of refractory hidradenitis suppurativa with axillary involvement, failed adalimumab and infliximab, and good clinical response to roflumilast at 12 weeks, with associated weight loss.<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">58</span></a> Gyldenløve et al. reported 2 cases of recurrent oral aphthosis treated with oral roflumilast 500<span class="elsevierStyleHsp" style=""></span>μg/day, showing proper and rapid responses within 2 to 3 weeks and maintained responses after 3 months of treatment.<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">59</span></a> Similarly, they also described 1 case of nummular eczema with failed multiple treatments that, somehow, achieved an early and sustained response to oral roflumilast, without visible adverse events being reported.<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">60</span></a> There was also 1 case of erosive oral lichen planus refractory to first-line therapies and on systemic corticosteroids. Oral roflumilast allowed for down-titration of prednisone to 2.5<span class="elsevierStyleHsp" style=""></span>mg/day at 3 months.<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">61</span></a> A Spanish group recently reported 1 case of refractory Behçet's disease successfully treated with roflumilast 250<span class="elsevierStyleHsp" style=""></span>μg/day, without significant adverse events being reported.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">62</span></a> Finally, a stage IV clinical trial (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>40) currently in the recruitment stage is evaluating oral roflumilast at a dose of 500<span class="elsevierStyleHsp" style=""></span>μg/day vs placebo to treat chronic hand eczema.<a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">63</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Dermatoses that could potentially benefit from roflumilast</span><p id="par0075" class="elsevierStylePara elsevierViewall">Given its mechanism of action, which is similar to that of apremilast and the possibility of elevated PDE4 levels, multiple dermatoses in which this drug has been used off-label could potentially benefit from oral or topical roflumilast (<a class="elsevierStyleCrossRef" href="#tbl0030">table 6</a>). Among these we find primarily autoimmune dermatoses like vitiligo or alopecia areata,<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> erythematosquamous diseases similar to psoriasis such as pityriasis rubra pilaris,<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">64</span></a> or Sneddon-Wilkinson syndrome,<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">65</span></a> blistering diseases such as vulgar pemphigus or acquired epidermolysis bullosa,<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> genodermatoses such as familial benign pemphigus (Hailey-Hailey disease),<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">66</span></a> or ichthyosis.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> Other diseases where apremilast could also be useful include hidradenitis suppurativa,<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">67</span></a> cutaneous lichen planus,<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">68</span></a> or other lichenoid and interface dermatitis,<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">69</span></a> cutaneous lupus erythematosus<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">70</span></a>, or cutaneous sarcoidosis.<a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">71</span></a> Its potential application in morphea, a relatively common disease where PDE4i have shown to reduce dermal fibrosis is of special interest. In fact, good results have been reported with apremilast to treat this entity.<a class="elsevierStyleCrossRefs" href="#bib0790"><span class="elsevierStyleSup">72–74</span></a></p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">The management of moderate-to-severe inflammatory dermatoses often requires the use of immunomodulators or immunosuppressants, which are often used off-label in dermatology. Despite the addition of small molecules and biologic agents to our therapeutic arsenal, there is a need for new cost-effective immunomodulatory therapies with a good safety profile.<a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">75–77</span></a> One significant advantage of roflumilast is that it is not expensive (nearly €30/month in Spain for the oral formulation of 500<span class="elsevierStyleHsp" style=""></span>μg/day, which is similar to the price reported in other countries).<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">59</span></a> In fact, its price is lower than that of classic immunosuppressants such as oral cyclosporine or subcutaneous methotrexate. Another advantage is its excellent safety profile, with few contraindications and mostly GI AEs, which is very similar to what has already been reported with apremilast. Regarding serious AEs, a still-to-be elucidated relationship has been suggested on the use of roflumilast and atrial fibrillation. The association between roflumilast and suicide is also controversial and has not been found in subsequent studies.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">37,43</span></a> This drug has been on the market for over 10 years. During this time no new AEs or deleterious cumulative effects have ever been reported from its long-term use.<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">44,45</span></a> However, GI AEs can be very bothersome and lead to its discontinuation in a significant number of patients. Therefore, proper titration is essential, with gradual up-titration. Overall, it is recommended to start at a dose of 250<span class="elsevierStyleHsp" style=""></span>μg/day with or without food and always at the same time of day. With proper responses and in the absence of significant AEs, up-titrating to the optimal dose of 500<span class="elsevierStyleHsp" style=""></span>μg/day is advised. Its use has been tested for up to 1 year, although it may be continued for longer periods of time at the physician's discretion.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">23</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Convenient dosing and the possibility of dual application, both topically and orally are among the advantages of roflumilast.<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">78</span></a> Additionally, it may lead to weight loss associated with an improved metabolic profile and insulin resistance, which makes it a perfect option for patients with dermatoses and overweight, such as those with hidradenitis suppurativa.<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">58</span></a> However, this needs to be demonstrated in prospective studies with proper follow-up.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Regarding its topical use, roflumilast should be applied once a day, with a small layer being applied to the affected skin. It is not yet available in Spain.</p><p id="par0095" class="elsevierStylePara elsevierViewall">Its application in dermatology parallels former studies on apremilast, another PDE4i with a similar affinity to PDE4 and no higher frequency of side events. However, to date, no studies have compared the side effect profiles of apremilast and roflumilast.<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">79</span></a> In our review, we found that roflumilast has been used off-label in its oral form to treat various dermatoses (<a class="elsevierStyleCrossRef" href="#tbl0025">table 5</a>), including psoriasis, hidradenitis suppurativa,<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">58</span></a> recurrent oral aphthosis,<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">59</span></a> Behçet's disease,<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">62</span></a> erosive oral lichen planus,<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">61</span></a> and nummular eczema,<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">60</span></a> among others. Also, its pharmacokinetic and pharmacodynamic analogy to apremilast allows us to hypothesize that it could be useful to treat multiple skin diseases. However, the evidence available to date is still limited and recommendations on this regard cannot be made yet. In the coming years, new indications for oral or topical roflumilast in dermatology may be approved, and dermatologists still need to become familiar with this promising drug.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Limitations</span><p id="par0100" class="elsevierStylePara elsevierViewall">This review has the limitation of being narrative and not a systematic review or meta-analysis. Additionally, many of the studies included, especially those on off-label uses of roflumilast, are case series, have small sample sizes, or a retrospective design. Additionally, its potential uses have been extrapolated from apremilast due to pharmacokinetic and pharmacodynamic analogies. All these factors make it difficult to generalize the findings reported and draw definitive conclusions.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Conclusions</span><p id="par0105" class="elsevierStylePara elsevierViewall">Roflumilast is a drug that has been approved in dermatology to treat plaque psoriasis and mild-to-moderate seborrheic dermatitis, both in topical formulations. There are reports and studies available, most small, which support the utility of oral roflumilast to treat psoriasis, hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, and lichen planus, among others. It has a very favorable safety profile, is cost-effective, and is widely available. New controlled studies are needed to assess its efficacy profile in inflammatory dermatoses and establish new approved indications for this promising molecule.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conflicts of interest</span><p id="par0110" class="elsevierStylePara elsevierViewall">None declared.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres2103272" "titulo" => "Graphical abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:3 [ "identificador" => "xres2103273" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 2 => array:2 [ "identificador" => "xpalclavsec1792344" "titulo" => "Keywords" ] 3 => array:3 [ "identificador" => "xres2103271" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0015" ] ] ] 4 => array:2 [ "identificador" => "xpalclavsec1792345" "titulo" => "Palabras clave" ] 5 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 6 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:6 [ 0 => array:3 [ "identificador" => "sec0015" "titulo" => "Roflumilast pharmacokinetics and mechanism of action" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Pharmacokinetics (table 2)" ] ] ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Mechanism of action and pharmacodynamics" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Safety profile" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Approved indications in dermatology" ] 4 => array:2 [ "identificador" => "sec0040" "titulo" => "Off-label use of roflumilast in dermatology" ] 5 => array:2 [ "identificador" => "sec0045" "titulo" => "Dermatoses that could potentially benefit from roflumilast" ] ] ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "Limitations" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Conclusions" ] 10 => array:2 [ "identificador" => "sec0065" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-06-22" "fechaAceptado" => "2023-09-04" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1792344" "palabras" => array:6 [ 0 => "Roflumilast" 1 => "Dermatology" 2 => "Psoriasis" 3 => "Apremilast" 4 => "Phosphodiesterase" 5 => "Off-label" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1792345" "palabras" => array:6 [ 0 => "Roflumilast" 1 => "Dermatología" 2 => "Psoriasis" 3 => "Apremilast" 4 => "Fosfodiesterasa" 5 => "<span class="elsevierStyleItalic">Off-label</span>" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case reports and small series have also reported successful outcomes in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease. Roflumilast has a favorable safety profile, similar to that of apremilast, and it is considerably cheaper than new generation drugs and even some conventional immunosuppressants. We review the pharmacokinetics and pharmacodynamics of topical and oral roflumilast and discuss potential adverse effects and both approved and off-label uses in dermatology. Roflumilast is a promising agent to consider.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Roflumilast es un inhibidor de la fosfodiesterasa-4 aprobado de forma oral para la prevención de exacerbaciones en pacientes con enfermedad pulmonar obstructiva crónica y fenotipo de bronquitis crónica. En dermatología, el roflumilast tópico está aprobado por la <span class="elsevierStyleItalic">Food and Drug Administration</span> en psoriasis en placas y dermatitis seborreica leve/moderada. En cuanto a su uso fuera de indicación, hemos encontrado un ensayo clínico que avala la utilidad del roflumilast oral en psoriasis, así como pequeñas series de casos o casos clínicos aislados en hidradenitis supurativa, aftosis oral recurrente, eccema numular, liquen plano y enfermedad de Behçet. Su perfil de seguridad es favorable, similar al del apremilast, y su coste es considerablemente inferior a los de los fármacos de nueva generación, o incluso al de algunos inmunosupresores clásicos. Presentamos una revisión de roflumilast tópico y oral, en términos de farmacocinética y farmacodinámica, efectos adversos, usos dermatológicos aprobados y fuera de indicación. Roflumilast es un agente prometedor en dermatología.</p></span>" ] ] "multimedia" => array:9 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 599 "Ancho" => 1677 "Tamanyo" => 55093 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Biochemical structure of roflumilast (A) and its active metabolite, roflumilast N-oxide (B). Note the addition of an oxygen radical in the active form to one of the peripheral hexagonal rings and the removal of a proton in the middle ring (highlighted in red).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 3860 "Ancho" => 2935 "Tamanyo" => 772789 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Mechanism of action of roflumilast. Phosphodiesterase inhibitors lead to an accumulation of intracellular cAMP by interfering with its degradation. The increased intracellular concentration of cAMP results in the inhibition of chemotaxis, reduced inflammatory cell infiltration, and decreased release of inflammatory and cytotoxic mediators, thereby reducing inflammation.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">5’-AMP, 5’-adenylic acid; AC, adenylate cyclase; ATF, activating transcription factor 1; ATP, adenosine triphosphate; Bcl-6, B-cell lymphoma protein 6; c-AMP, cyclic adenosine monophosphate; CREB, cAMP responsive element; Egr-1, early growth response protein 1; Elk-1, E-26-like protein 1; ERK, extracellular signal-regulated kinase; GP, G protein; GPCR, G protein-coupled receptors; IKKbeta, inhibitor of nuclear factor kappa-B kinase subunit beta; IPDE-4, inhibitor of phosphodiesterase type 4; MAPK, mitogen-activated protein kinases; NFKB, nuclear factor KB; PDE4, phosphodiesterase type 4; PDE4i, phosphodiesterase type 4 inhibitor; PKA, protein kinase A; Raf, rapidly accelerated fibrosarcoma protein kinases; RTK, receptor tyrosine kinases.<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">34</span></a></p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Clinical signs \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Disease and study endpoints \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Primary reference \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pulmonary</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prevention of COPD exacerbations, phenotype CB (only approved use) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trials (stage IV) <span class="elsevierStyleInterRef" id="intr0005" href="ctgov:NCT00297102">NCT00297102</span> and <span class="elsevierStyleInterRef" id="intr0010" href="ctgov:NCT00297115">NCT00297115</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">14</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prevention of asthma exacerbations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trials (stage III) <span class="elsevierStyleInterRef" id="intr0015" href="ctgov:NCT01365533">NCT01365533</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">15</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement of thr asthma-COPD overlap syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Narrative literature review \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">16</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of chronic cough \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trials (stage IV) <span class="elsevierStyleInterRef" id="intr0020" href="ctgov:NCT01443845">NCT01443845</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">17</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prevention of exacerbations in bronchiectasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trials (stage III) <span class="elsevierStyleInterRef" id="intr0025" href="ctgov:NCT01580748">NCT01580748</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">18</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Relief in symptomatic COVID-19-related infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Narrative literature review. Unregistered in clinicaltrials.gov \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">19</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oncological \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement in association with conventional chemotherapy in diffuse large B-cell lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In vitro and animal studies (stage I) <span class="elsevierStyleInterRef" id="intr0030" href="ctgov:NCT03458546">NCT03458546</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">38</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Traumatological \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Optimization of walking in spinal cord injuries \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In vitro and animal studies (stage I) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">80</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neuropsychiatric</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of cognitive impairment and Alzheimer's disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ongoing randomized clinical trials (stage II) <span class="elsevierStyleInterRef" id="intr0035" href="ctgov:NCT04658654">NCT04658654</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">8</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement in schizophrenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ongoing randomized clinical trials (stage I) <span class="elsevierStyleInterRef" id="intr0040" href="ctgov:NCT02079844">NCT02079844</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">9</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fewer depressive symptoms as an adjuvant to other antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ongoing randomized clinical trials (stage II) <span class="elsevierStyleInterRef" id="intr0045" href="ctgov:NCT04751071">NCT04751071</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">10</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of peripheral neuropathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage II) <span class="elsevierStyleInterRef" id="intr0050" href="ctgov:NCT05884281">NCT05884281</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">11</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement of fragile X syndrome compared to baclofen and metformin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Uncompleted randomized clinical trial (stage II) <span class="elsevierStyleInterRef" id="intr0055" href="ctgov:NCT05163808">NCT05163808</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">12</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of alcohol consumption in vitro \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage I).Unregistered in clinicaltrials.gov \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">13</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Digestive</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Potential reduction of ulcerative colitis flares \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ongoing clinical trial (stage I) <span class="elsevierStyleInterRef" id="intr0060" href="ctgov:NCT05684484">NCT05684484</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0835"><span class="elsevierStyleSup">81</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Evaluation of roflumilast vs pioglitazone in non-alcoholic steatohepatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trial (stage II) <span class="elsevierStyleInterRef" id="intr0065" href="ctgov:NCT01703260'">NCT01703260</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">82</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Endocrinological</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of roflumilast in type II diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed randomized clinical trial (stage II) <span class="elsevierStyleInterRef" id="intr0070" href="ctgov:NCT01140542">NCT01140542</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">83</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of insulin and glucose levels in obese prediabetic patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage II) <span class="elsevierStyleInterRef" id="intr0075" href="ctgov:NCT01862029">NCT01862029</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">41</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement of polycystic ovary syndrome compared to metformin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage IV) <span class="elsevierStyleInterRef" id="intr0080" href="ctgov:NCT02037672">NCT02037672</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">84</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduction of diabetic neuropathy compared to alpha-lipoic acid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage III) <span class="elsevierStyleInterRef" id="intr0085" href="ctgov:NCT05369793">NCT05369793</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">85</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Renal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement of analytical parameters of diabetic nephropathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed non-randomized clinical trial (stage III) <span class="elsevierStyleInterRef" id="intr0090" href="ctgov:NCT04755946">NCT04755946</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">86</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479600.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Uses of roflumilast in non-dermatological diseases.<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">8,38,80-86</span></a></p>" ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Item \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oral roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Topical roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Indications approved by the FDA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prevention of COPD exacerbations, phenotype CB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Plaque psoriasisSeborrheic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pharmacokinetics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Oral bioavailability: 80% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Possibility of systemic absorption \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Half-life: between 17 and 30 hours \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Half-life around 24 hours \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Metabolism: almost exclusively hepatic. Conversion to active metabolite N-oxide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Metabolism: almost exclusively hepatic. Conversion to active metabolite N-oxide \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Excretion: 70% renal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">→ Excretion: cutaneous and the absorbed systemic portion, mostly renal \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dosage \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">250<span class="elsevierStyleHsp" style=""></span>μg/day for 28 days followed by 500<span class="elsevierStyleHsp" style=""></span>μg/day for maintenance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Application of a thin layer to affected lesions. Approved at a concentration of 0.3% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Administration \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral with or without food, diluted in water \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 application/day (thin layer). Avoid in ocular, oral, or intravaginal region \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Contraindications \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hypersensitivity to the active substance or to any of its excipients.<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>Moderate or severe hepatic impairment (Child-Pugh class B or C) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hypersensitivity to the active substance or any of its excipients.<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>Moderate or severe hepatic impairment (Child-Pugh class B or C) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pharmacological interactions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mainly metabolized by cytochromes CYP3A4 and CYP1A2. May require dose titration in patients with inducers or inhibitors of these cytochromes. The use of contraception with gestodene and ethinylestradiol can increase its toxicity.<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mainly metabolized by cytochromes CYP3A4 and CYP1A2. May require dose titration in patients with inducers or inhibitors of these cytochromes. The use of contraception with gestodene and ethinylestradiol can increase its toxicity.<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Titration in liver failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Caution in mild liver failure (Child-Pugh class A) and contraindicated in moderate or severe liver failure (Child-Pugh class B or C) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Caution in mild liver failure (Child-Pugh class A) and contraindicated in moderate or severe liver failure (Child-Pugh class B or C) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Titration in kidney disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No dose titration required \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No dose titration required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Titration in elderly patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No dose titration required \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No dose titration required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pregnancy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Data on the use of roflumilast in pregnant women are scarce. Animal studies have shown reproductive toxicity, which is why its use in pregnant women is ill-advised \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Data on the use of roflumilast in pregnant women are scarce. Animal studies have shown reproductive toxicity, which is why its use in pregnant women is ill-advised \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Contraception \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Women of childbearing age should use effective contraception methods during treatment. Avoid gestodene and ethinylestradiol<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">May be considered if necessary. Avoid gestodene and ethinylestradiol<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Breastfeeding \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pharmacokinetic data available in animals reveal that roflumilast or its metabolites are excreted through breast milk, which is why its use in pregnant women is ill-advised \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Possible. Avoid application in the breast area during application \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pediatric \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Approved in kids ≥ 12 years. No studies have assessed its efficacy in kids <<span class="elsevierStyleHsp" style=""></span>12 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Approved in kids ≥ 12 years. No studies have assessed its efficacy in kids <<span class="elsevierStyleHsp" style=""></span>12 years \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Follow-up \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Periodic reviews of weight and mood swings (every 3 to 6 months). No specification of blood tests during follow-up by the FDA and EMA. Recommended baseline blood tests with suspected liver failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No follow-up required \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479601.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Hypersensitivity is not listed by the FDA. However, it is listed by CIMA/AEMPS.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">In a drug interaction study with an oral contraceptive containing gestodene and ethinylestradiol, the overall PDE4 inhibitory activity went up by 17%.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Characteristics of roflumilast.<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">8,38,41,80-86</span></a></p>" ] ] 4 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">—: Not described or anecdotal reports; AST, aspartate aminotransferase; CPK, creatine phosphokinase; GGT, gamma-glutamyltransferase.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Frequency \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Common (≥ 1/100 to <<span class="elsevierStyleHsp" style=""></span>1/10)</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Uncommon (≥ 1/1000 to <<span class="elsevierStyleHsp" style=""></span>1/100)</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Rare (≥ 1/10 000 to <<span class="elsevierStyleHsp" style=""></span>1/1000)</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Organ classification \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oral roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Topical roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oral roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Topical roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oral roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Topical roflumilast \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Immune system disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hypersensitivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hypersensitivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hives and angioderma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hives and angioderma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Endocrine disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gynecomastia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metabolism and nutrition disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Weight lossDecreased appetite \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Weight decreaseDecreased appetite \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psychiatric disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insomnia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AnxietyInsomnia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insomnia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Suicidal ideation and behavior,<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> depression, nervousness, panic attacks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nervous system disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TremorVertigoDizziness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TremorVertigoDizziness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dysgeusia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cardiac disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Palpitations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Respiratory, thoracic, and mediastinal disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Respiratory tract infections (excluding pneumonia) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Respiratory tract infections (excluding pneumonia) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Urinary tract disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Urinary tract infections \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Urinary tract infections \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GI disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diarrhea, nausea, abdominal pain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diarrhea, nausea, abdominal pain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gastritis, vomiting, gastroesophageal reflux, dyspepsia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hematochezia, constipation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hepatobiliary disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Elevated GGT and AST levels \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skin and subcutaneous tissue disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Burning at the application site \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nonspecific maculopapular rash \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pain at the application site \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hives and angioedema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hives and angioedema \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Musculoskeletal and connective tissue disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Muscle spasms and weakness, myalgia, back pain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Elevated CPK levels \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">General disorders and changes to the administration site \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Malaise, asthenia, fatigue \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">— \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479598.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">In clinical trials and post-marketing surveillance, rare cases of suicidal ideation and behavior, including suicide, have been reported.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">37,43</span></a></p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Adverse events associated with the use of roflumilast.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">COPD, chronic obstructive pulmonary disease; IGA, Investigator's Global Assessment Scale; PSSI, Psoriasis Scalp Severity Index; SR, systematic review.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dermatosis \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Year, authors \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study endpoints \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Results \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="7" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Plaque psoriasis</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Kircik L et al.<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">6</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">304 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IIb randomized clinical trial \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of an 8-week course of 0.3% topical roflumilast vs placebo to treat plaque psoriasis on the body and scalp. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A significantly larger number of patients treated with roflumilast (59.1%) compared to patients treated with the vehicle (11.4%) achieved the IGA endpoint on the scalp on week 8 (<span class="elsevierStyleItalic">P</span> <<span class="elsevierStyleHsp" style=""></span>.0001). There was also a significant improvement in secondary endpoints, including body IGA, scalp itch scale, and PSSI. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Thurston Jr et al.<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">82</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Review of 495 patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Post-trial study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Post-trial study of several stage II clinical trials that assessed the pharmacokinetic characteristics of topical 0.3% roflumilast to treat plaque psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Systemic bioavailability of 1.5%. Skin concentration 61 to 126 times higher compared to oral administration.Roflumilast N-oxide action 8 times higher compared to roflumilast. This effect, however, has not been reported with the topical formulation.Half-life of 4 days \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Stein Gold L et al.<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">50</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">331 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IIb randomized clinical trial \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Evaluation of itching in patients with plaque psoriasis after a 12-week course of 0.3%, 0.15% topical roflumilast and placebo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3% topical roflumilast worked better treating itching and night-time relief compared to 0.15% topical roflumilast and placebo. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Pixley J et al.<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">78</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Review of 2064 patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">It included several stage III clinical trials on the effectiveness of topical roflumilast to treat plaque psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3% topical roflumilast is an effective and safe drug to treat plaque and intertriginous psoriasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Arcutis biotherapeutics clinical trial<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">79</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">332 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage III randomized clinical trial \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Efficacy and safety profile of a 52-week course of 0.3% topical roflumilast vs vehicle control to treat plaque and intertriginous psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">45% of the topical roflumilast group achieved the IGA endpoint (improvement ≥ 2 points compared to baseline) vs 6.1% of the control group \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Lebwohl MG et al.<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">27</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">439 (DERMIS-1 trial) and 442 (DERMIS 2 trial) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage III randomized clinical trials \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Efficacy and safety profile of an 8-week course of 0.3% topical roflumilast vs vehicle to treat plaque intertriginous psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42.4% of the patients from the group on topical roflumilast achieved the IGA endpoint compared to 6.1% of the control group (DERMIS-1), and the efficacy of topical roflumilast reached 37.5% in the IGA endpoint (improvement ≥ 2 scores from baseline) compared to 6.9% from the control group (DERMIS-2). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2020, Papp A et al.<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">49</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage I randomized clinical trial (safety)/IIa (dose) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of a 4-week course of 0.5% topical roflumilast vs 0.15% placebo to treat plaque psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The primary endpoint (plaque clearance) was achieved in 66% and 67% of the patients from the 0.5% and 0.15% roflumilast groups, respectively, compared to 35% from the placebo group. No differences were reported regarding side effects. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Seborrheic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Zirwas MJ et al.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">7</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">226 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IIa randomized clinical trial \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Efficacy and safety profile of an 8-week course of 0.3% topical roflumilast vs placebo to treat mild-to-moderate seborrheic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Perfil de seguridad adecuadoEfficacy and safety profile of an 8-week course of 0.3% topical roflumilast vs placebo to treat mild-to-moderate seborrheic dermatitis. Proper safety profile \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479597.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Studies on topical roflumilast to treat plaque psoriasis and seborrheic dermatitis.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">6,7,27,49,50,78,79,82</span></a></p>" ] ] 6 => array:8 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at5" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">HS, hidradenitis suppurativa; UVB, ultraviolet-B Radiation therapy.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dermatosis \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Year, authors \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study endpoints \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Results \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Gyldenløve M et al.<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">45</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage III randomized clinical trial <span class="elsevierStyleInterRef" id="intr0095" href="ctgov:NCT04549870">NCT04549870</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile profile of oral roflumilast to treat plaque psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">At week 12, 35% of the patients achieved PASI 75 vs 13% from the placebo group (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.014). Two patients required discontinuation due to roflumilast-related adverse events being diarrhea the most common adverse event of all. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2021, Egeberg A et al.<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">56</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48-year-old man with plaque psoriasis treated with oral roflumilast 500<span class="elsevierStyleHsp" style=""></span>μg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Complete clearance of lesions after 24 weeks on therapy. No adverse events reported. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Gyldenløve M et al.<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">57</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the long-term efficacy and safety profile of oral roflumilast in the patient from the former study<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">56</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">After 18 months of treatment, the patient maintained PASI 0 and had no notable adverse events. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2017, Michels K et al.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">48</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59-year-old man with COPD and erythrodermic psoriasis successfully treated with oral roflumilast 500<span class="elsevierStyleHsp" style=""></span>μg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improvement in psoriasis occurred incidentally after COPD treatment. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Ring et al.<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">58</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the response to oral roflumilast in a patient with severe axillary HS on failed adalimumab and infliximab therapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adequate response with fewer lesions reported, and no notable adverse events at 3 months. Associated with a 9 kg weight loss. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recurrent oral aphthosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Gyldenløve et al.<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">59</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case series \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the response to oral roflumilast in 2 patients with recurrent oral aphthosis who did not meet Behçet's disease criteria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Complete lesion resolution occurred early (2 to 3 weeks) and was sustained after 3 months of treatment. Good safety profile. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Behçet's disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Peñuelas et al.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">62</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the response to oral roflumilast 250<span class="elsevierStyleHsp" style=""></span>μg/day in a patient with refractory Behçet's disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Favorable response to roflumilast therapy without noticeable adverse events. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nummular eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2022, Gyldenløve et al.<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">60</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the response to oral roflumilast 500<span class="elsevierStyleHsp" style=""></span>μg/day in a 69-year-old patient with nummular eczema refractory to topical steroids, UVB, methotrexate, and azathioprine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Early response (2 weeks) and complete lesion clearance after 3 months of treatment. Good safety profile. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erosive lichen planus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2023, Fage et al.<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">61</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case report \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the response to oral roflumilast in a patient with erosive oral lichen planus refractory to topical and oral steroids, methotrexate, cyclosporine, azathioprine, apremilast, and adalimumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Substantial resolution of lesions after 3 months of treatment, initially concomitant with descending prednisone (7.5 mg to 2.5 mg after 3 months on roflumilast). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Atopic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical trial<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">51</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IIa clinical trial <span class="elsevierStyleInterRef" id="intr0100" href="ctgov:NCT01856764">NCT01856764</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of 0.5% topical roflumilast vs placebo to treat atopic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No superior results were achieved compared to placebo in the roflumilast group. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Atopic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical trial<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">52</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">136 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IIa clinical trial <span class="elsevierStyleInterRef" id="intr0105" href="ctgov:NCT04773587">NCT04773587</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of 0.15% topical roflumilast vs 0.05% topical roflumilast vs placebo to treat atopic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A decrease in EASI of 6.4 points in the 0.15% roflumilast group, 6 points in the 0.05% roflumilast group, and 4.8 points in the control group, without statistical significance. Good safety profile. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic hand eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical trial<a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">63</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IV clinical trial (Recruitment in progress) <span class="elsevierStyleInterRef" id="intr0110" href="ctgov:NCT05682859">NCT05682859</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of oral roflumilast vs placebo to treat chronic hand eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Results pending publication \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic hand eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical trial<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">53</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">230 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed stage IIa clinical trial <span class="elsevierStyleInterRef" id="intr0115" href="ctgov:NCT04378569">NCT04378569</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of 0.3% vs 0.1% topical roflumilast vs placebo to treat chronic hand eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Results pending publication \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rosacea \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical trial<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">54</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Completed stage II clinical trial (Results pending publication) <span class="elsevierStyleInterRef" id="intr0120" href="ctgov:NCT05278624">NCT05278624</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Assess the efficacy and safety profile of 0.5% topical roflumilast vs placebo to treat papulopustular rosacea \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Results pending publication \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479599.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Clinical trials on the off-label use of roflumilast in dermatology.<a class="elsevierStyleCrossRefs" href="#bib0655"><span class="elsevierStyleSup">45,48,51-54,56-63</span></a></p>" ] ] 7 => array:8 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at6" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">SAPHO, synovitis acne pustulosis hyperostosis osteitis.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Alopecia areata<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Frontal fibrosing alopecia<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Central centrifugal cicatricial alopecia<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic actinic dermatitis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lichenoid interface dermatitis<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">69</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Atopic dermatitis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Refractory seborrheic dermatitis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic hand eczema<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nummular eczema<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Behçet's disease<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acquired epidermolysis bullosa<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Perforating diseases<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erythema annulare centrifugum<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recurrent erythema multiforme<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Leprous nodular erythema<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recurrent aphthous stomatitis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decalvans folliculitis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Granuloma annulare<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Orofacial granulomatosis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hidradenitis suppurativa<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">67</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lamellar ichthyosis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dermatomyositis skin lesions<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lichen planus<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">68</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mucosal lichen planus<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lichen planopilaris<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Discoid cutaneous lupus erythematosus<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">70</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Morphea<a class="elsevierStyleCrossRefs" href="#bib0790"><span class="elsevierStyleSup">72–74</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pyoderma gangrenosum<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">P-2003 pemphigoid<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pityriasis rubra pilaris<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">64</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nodular prurigo<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Palmoplantar pustulosis<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Palmoplantar keratoderma<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rosacea<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sarcoidosis<a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">71</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sneddon-Wilkinson syndrome<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">65</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SAPHO syndrome<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vitiligo<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vulgar pemphigus<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Benign familial pemphigus<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">66</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral ulcers<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3479596.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Off-label use of apremilast and potential uses of roflumilast in dermatology.</p>" ] ] 8 => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 824 "Tamanyo" => 91465 ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:86 [ 0 => array:3 [ "identificador" => "bib0435" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologics in dermatology: What does the future hold?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C. Yavuz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dth.12932" "Revista" => array:5 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2019" "volumen" => "32" "paginaInicial" => "e12932" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30977240" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0440" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast for psoriasis treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.-M. Carrascosa" 1 => "E. del Alcazar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.23736/S0392-0488.20.06684-5" "Revista" => array:6 [ "tituloSerie" => "G Ital Dermatol Venereol" "fecha" => "2020" "volumen" => "155" "paginaInicial" => "421" "paginaFinal" => "433" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32545946" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0445" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast in dermatology: A review of literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D. Nassim" 1 => "A. Alajmi" 2 => "A. Jfri" 3 => "K. Pehr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2020" "volumen" => "33" "paginaInicial" => "e14261" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0450" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.F. Eichenfield" 1 => "R.G. Gower" 2 => "J. Xu" 3 => "M.S. Alam" 4 => "J.C. Su" 5 => "D.E. Myers" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40257-023-00780-w" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2023" "volumen" => "24" "paginaInicial" => "623" "paginaFinal" => "635" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37184828" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0455" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast: A Review in COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "K.P. Garnock-Jones" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40265-015-0463-1" "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2015" "volumen" => "75" "paginaInicial" => "1645" "paginaFinal" => "1656" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26338438" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0460" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled stage 2b study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.H. Kircik" 1 => "J. Alonso-Llamazares" 2 => "N. Bhatia" 3 => "M. Bukhalo" 4 => "A.R. Devani" 5 => "Z.D. Draelos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2023" "paginaInicial" => "ljad182" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0465" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Stage 2a Randomized Clinical Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Zirwas" 1 => "Z.D. Draelos" 2 => "J. DuBois" 3 => "L.H. Kircik" 4 => "A.Y. Moore" 5 => "L. Stein Gold" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "JAMA Dermatol" "fecha" => "2023" "paginaInicial" => "e230846" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0470" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A Proof of Concept Stage II Study With the PDE4 Inhibitor Roflumilast in Patients With (Amnestic) Mild Cognitive Impairment (MCI) or Mild Dementia" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Maastricht University Medical Center" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2022" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0475" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Takeda" 1 => "Randomized" 2 => "Double-Blind" 3 => "Placebo Controlled" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2016" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0480" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients. Proof-of-Concept, Randomized, Double-Blind Placebo-Controlled Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.S. Abdallah" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2023" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0485" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of Roflumilast in Prevention of Peripheral Neuropathy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "N. Mansour" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2023" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0490" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Children's Hospital Medical Center, Cincinnati" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2023" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0495" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "X. Liu" 1 => "P.-D. Hao" 2 => "M.-F. Yang" 3 => "J.-Y. Sun" 4 => "L.-L. Mao" 5 => "C.-D. Fan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00213-017-4631-8" "Revista" => array:6 [ "tituloSerie" => "Psychopharmacology (Berl)" "fecha" => "2017" "volumen" => "234" "paginaInicial" => "2409" "paginaFinal" => "2419" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28477089" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0500" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.M.A. Calverley" 1 => "K.F. Rabe" 2 => "U.-M. Goehring" 3 => "S. Kristiansen" 4 => "L.M. Fabbri" 5 => "F.J. Martinez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(09)61255-1" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2009" "volumen" => "374" "paginaInicial" => "685" "paginaFinal" => "694" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19716960" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0505" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.M. Gauvreau" 1 => "L.P. Boulet" 2 => "C. Schmid-Wirlitsch" 3 => "J. Côté" 4 => "M. Duong" 5 => "K.J. Killian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1465-9921-12-140" "Revista" => array:5 [ "tituloSerie" => "Respir Res" "fecha" => "2011" "volumen" => "12" "paginaInicial" => "140" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22029856" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0510" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The asthma-chronic obstructive pulmonary disease overlap syndrome: Pharmacotherapeutic considerations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Louie" 1 => "A.A. Zeki" 2 => "M. Schivo" 3 => "A.L. Chan" 4 => "K.Y. Yoneda" 5 => "M. Avdalovic" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/ecp.13.2" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Pharmacol" "fecha" => "2013" "volumen" => "6" "paginaInicial" => "197" "paginaFinal" => "219" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23473596" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0515" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Effect of roflumilast on cough and sputum in patients with severe or very severe chronic obstructive pulmonary disease (COPD) receiving inhaled combination therapy: Evaluation of the exacerbation of chronic pulmonary disease tool-patient reported outcomes (exact-pro) subdomain scores | Cochrane Library s.f." ] ] ] 17 => array:3 [ "identificador" => "bib0520" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "University of Sao Paulo General Hospital" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2020" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0525" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.L. Jabaris" 1 => "V. Ranju" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pupt.2020.101978" "Revista" => array:5 [ "tituloSerie" => "Pulm Pharmacol Ther." "fecha" => "2021" "volumen" => "66" "paginaInicial" => "101978" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33259924" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0530" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast Altana Pharma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P. Reid" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Opin Investig Drugs" "fecha" => "2002" "volumen" => "3" "paginaInicial" => "1165" "paginaFinal" => "1170" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12211409" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0535" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.D. Bethke" 1 => "G.M. Böhmer" 2 => "R. Hermann" 3 => "B. Hauns" 4 => "R. Fux" 5 => "K. Mörike" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0091270006294529" "Revista" => array:6 [ "tituloSerie" => "J Clin Pharmacol" "fecha" => "2007" "volumen" => "47" "paginaInicial" => "26" "paginaFinal" => "36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17192499" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0540" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Hatzelmann" 1 => "C. Schudt" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pharmacol Exp Ther" "fecha" => "2001" "volumen" => "297" "paginaInicial" => "267" "paginaFinal" => "279" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0545" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "CIMA. Agencia Española de Medicamentos y Productos Sanitarios. Roflumilast. Ficha técnica. Disponible en: <a target="_blank" href="https://cima.aemps.es/cima/pdfs/es/ft/85529/85529_ft.pdf">https://cima.aemps.es/cima/pdfs/es/ft/85529/85529_ft.pdf</a>" ] ] ] 23 => array:3 [ "identificador" => "bib0550" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "K.F. Rabe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1476-5381.2011.01218.x" "Revista" => array:6 [ "tituloSerie" => "Br J Pharmacol" "fecha" => "2011" "volumen" => "163" "paginaInicial" => "53" "paginaFinal" => "67" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21232047" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0555" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Hauns" 1 => "R. Hermann" 2 => "A. Hünnemeyer" 3 => "R. Herzog" 4 => "D. Hauschke" 5 => "K. Zech" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0091270006291621" "Revista" => array:6 [ "tituloSerie" => "J Clin Pharmacol" "fecha" => "2006" "volumen" => "46" "paginaInicial" => "1146" "paginaFinal" => "1153" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16988203" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0560" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Crocetti" 1 => "G. Floresta" 2 => "A. Cilibrizzi" 3 => "M.P. Giovannoni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/molecules27154964" "Revista" => array:5 [ "tituloSerie" => "Molecules" "fecha" => "2022" "volumen" => "27" "paginaInicial" => "4964" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35956914" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0565" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.G. Lebwohl" 1 => "L.H. Kircik" 2 => "A.Y. Moore" 3 => "L. Stein Gold" 4 => "Z.D. Draelos" 5 => "M.J. Gooderham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2022.15632" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2022" "volumen" => "328" "paginaInicial" => "1073" "paginaFinal" => "1084" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36125472" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0570" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast (daliresp): A novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Baye" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "P T" "fecha" => "2012" "volumen" => "37" "paginaInicial" => "149" "paginaFinal" => "161" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22605906" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0575" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacodynamics: Molecular Mechanisms of Drug Action" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.K. Blumenthal" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "editores" => "L.L.Brunton, R.Hilal-Dandan, B.C.Knollmann" "titulo" => "Goodman & Gilman's: The Pharmacological Basis of Therapeutics" "serieFecha" => "2017" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0580" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesterase-4 inhibitors: Roflumilast [Article in Spanish]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.L. Izquierdo Alonso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0014-2565(11)70008-X" "Revista" => array:7 [ "tituloSerie" => "Rev Clin Esp" "fecha" => "2011" "volumen" => "211" "numero" => "Suppl 2" "paginaInicial" => "22" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21596170" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0585" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H. Li" 1 => "J. Zuo" 2 => "W. Tang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Front Pharmacol" "fecha" => "2018" "volumen" => "9" "paginaInicial" => "1048" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0590" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Defects and deficiency of adenyl cyclase in psoriatic skin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R.K. Wright" 1 => "S.H. Mandy" 2 => "K.M. Halprin" 3 => "S.L. Hsia" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1973" "volumen" => "107" "paginaInicial" => "47" "paginaFinal" => "53" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4345347" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0595" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.D. Bondarev" 1 => "M.M. Attwood" 2 => "J. Jonsson" …3 ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fphar.2022.1057083" "Revista" => array:5 [ "tituloSerie" => "Front Pharmacol" "fecha" => "2022" "volumen" => "13" "paginaInicial" => "1057083" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0600" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Reumatol Clin" "fecha" => "2016" "volumen" => "12" "paginaInicial" => "303" "paginaFinal" => "306" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0605" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Mol Immunol" "fecha" => "2009" "volumen" => "46" "paginaInicial" => "1925" "paginaFinal" => "1934" ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0610" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2011" "paginaInicial" => "CD002309" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0615" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Side-effects of roflumilast" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)60304-3" "Revista" => array:6 [ "tituloSerie" => "Lancet." "fecha" => "2012" "volumen" => "379" "paginaInicial" => "710" "paginaFinal" => "711" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0620" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4143/crt.2020.1371" "Revista" => array:6 [ "tituloSerie" => "Cancer Res Treat" "fecha" => "2022" "volumen" => "54" "paginaInicial" => "301" "paginaFinal" => "313" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0625" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7150/jca.21783" "Revista" => array:6 [ "tituloSerie" => "J Cancer" "fecha" => "2017" "volumen" => "8" "paginaInicial" => "3648" "paginaFinal" => "3656" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0630" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dom.12839" "Revista" => array:6 [ "tituloSerie" => "Diabetes Obes Metab" "fecha" => "2017" "volumen" => "19" "paginaInicial" => "496" "paginaFinal" => "508" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0635" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "National Heart, Lung, and Blood Institute (NHLBI)" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2018" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0640" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Takeda" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2016" ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0645" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1753465812466167" "Revista" => array:6 [ "tituloSerie" => "Ther Adv Respir Dis" "fecha" => "2013" "volumen" => "7" "paginaInicial" => "13" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0650" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A stage III, randomized controlled trial (ESTEEM 2)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.14164" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2015" "volumen" => "173" "paginaInicial" => "1387" "paginaFinal" => "1399" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0655" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.lanepe.2023.100639" "Revista" => array:5 [ "tituloSerie" => "Lancet Reg Health Eur" "fecha" => "2023" "volumen" => "30" "paginaInicial" => "100639" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0660" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug safety evaluation of roflumilast for the treatment of COPD: A meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/14740338.2016.1199683" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drug Saf" "fecha" => "2016" "volumen" => "15" "paginaInicial" => "1133" "paginaFinal" => "1146" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0665" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-Term Post-Marketing Observational Study of the Safety of Roflumilast" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejso.2024.108240" "Revista" => array:3 [ "tituloSerie" => "clinicaltrials.gov;" "fecha" => "2022" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0670" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating 2 Diseases With 1 Drug: PDE-4 Inhibitor for COPD and Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MJT.0000000000000465" "Revista" => array:6 [ "tituloSerie" => "Am J Ther" "fecha" => "2017" "volumen" => "24" "paginaInicial" => "e103" "paginaFinal" => "e104" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0675" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Stage 1/2a Randomized. Controlled Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.36849/JDD.2020.5370" "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2020" "volumen" => "19" "paginaInicial" => "734" "paginaFinal" => "740" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0680" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Stage 2b Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40257-022-00739-3" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2023" "volumen" => "24" "paginaInicial" => "305" "paginaFinal" => "313" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0685" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A Stage 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - A Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2016" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0690" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Stage 2 Proof of Concept Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.36849/JDD.7295" "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2023" "volumen" => "22" "paginaInicial" => "139" "paginaFinal" => "147" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0695" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A Stage 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Arcutis Biotherapeutics, Inc." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2022" ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0700" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov;" "fecha" => "2023" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0705" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Roflumilast enhances the melanogenesis and attenuates oxidative stress-triggered damage in melanocytes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdermsci.2023.04.001" "Revista" => array:6 [ "tituloSerie" => "J Dermatol Sci" "fecha" => "2023" "volumen" => "110" "paginaInicial" => "44" "paginaFinal" => "52" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0710" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.20602" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2021" "volumen" => "185" "paginaInicial" => "1251" "paginaFinal" => "1252" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0715" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term clearance of severe plaque psoriasis with oral roflumilast" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.18647" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2023" "volumen" => "37" "paginaInicial" => "e429" "paginaFinal" => "e430" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0720" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.21744" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2022" "volumen" => "187" "paginaInicial" => "813" "paginaFinal" => "815" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0725" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.21044" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2022" "volumen" => "187" "paginaInicial" => "258" "paginaFinal" => "259" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0730" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.18275" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2022" "volumen" => "36" "paginaInicial" => "e765" "paginaFinal" => "e766" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0735" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ced/llad041" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2023" "volumen" => "48" "paginaInicial" => "556" "paginaFinal" => "557" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0740" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Refractory Behçet's disease succesfully treated with Roflumilast" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2023" "paginaInicial" => "llad189" ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0745" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) - A Randomized Controlled Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2023" ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0750" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dth.13060" "Revista" => array:5 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2019" "volumen" => "32" "paginaInicial" => "e13060" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0755" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improvement of recalcitrant Sneddon-Wilkinson disease with apremilast" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajd.13253" "Revista" => array:6 [ "tituloSerie" => "Australas J Dermatol" "fecha" => "2020" "volumen" => "61" "paginaInicial" => "185" "paginaFinal" => "186" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0760" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast in benign chronic pemphigus (Hailey-Hailey disease)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ced.14225" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2020" "volumen" => "45" "paginaInicial" => "737" "paginaFinal" => "739" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0765" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2018.06.046" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2019" "volumen" => "80" "paginaInicial" => "80" "paginaFinal" => "88" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0770" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2013" "volumen" => "68" "paginaInicial" => "255" "paginaFinal" => "261" ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0775" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast for the off-label treatment of lichenoid and interface dermatoses" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2020.05.112" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2020" "volumen" => "83" "paginaInicial" => "1489" "paginaFinal" => "1491" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0780" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13555-013-0023-0" "Revista" => array:6 [ "tituloSerie" => "Dermatol Ther (Heidelb)" "fecha" => "2013" "volumen" => "3" "paginaInicial" => "1" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0785" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of apremilast in chronic cutaneous sarcoidosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2012" "volumen" => "148" "paginaInicial" => "262" "paginaFinal" => "264" ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0790" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2017" "volumen" => "76" "paginaInicial" => "1133" "paginaFinal" => "1141" ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0795" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Apremilast as a treatment for morphea: A case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JAAD Case Rep" "fecha" => "2022" "volumen" => "19" "paginaInicial" => "58" "paginaFinal" => "63" ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0800" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "This Month in JAAD Case Reports: April 2022: Apremilast for Morphea" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2022.01.015" "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2022" "volumen" => "86" "paginaInicial" => "744" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0805" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Practical Management of Immunosuppressants in Dermatology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2017.05.005" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr (Engl Ed)" "fecha" => "2018" "volumen" => "109" "paginaInicial" => "24" "paginaFinal" => "34" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0810" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologics in dermatology: What does the future hold?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dth.12932" "Revista" => array:5 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2019" "volumen" => "32" "paginaInicial" => "e12932" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0815" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546634.2018.1466022" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2018" "volumen" => "29" "paginaInicial" => "769" "paginaFinal" => "774" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0820" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "EMA. Summary of product characteristics. European Medicines Agency. s. f." ] ] ] 78 => array:3 [ "identificador" => "bib0825" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1124/jpet.116.232819" "Revista" => array:6 [ "tituloSerie" => "J Pharmacol Exp Ther" "fecha" => "2016" "volumen" => "358" "paginaInicial" => "413" "paginaFinal" => "422" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0830" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/pharmaceutics15051556" "Revista" => array:5 [ "tituloSerie" => "Pharmaceutics" "fecha" => "2023" "volumen" => "15" "paginaInicial" => "1556" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0835" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Youness ahmed magdy" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejso.2024.108240" "Revista" => array:3 [ "tituloSerie" => "clinicaltrials.gov;" "fecha" => "2023" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib0840" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multi-Center Stage 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2016" ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib0845" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of 500μg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Stage IIb, Proof of Concept Clinical Study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2016" ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib0850" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2014" ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib0855" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of Roflumilast in Prevention of Peripheral Neuropathy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2023" ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib0860" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical Study Evaluating the Possible Efficacy and Safety of Roflumilast in Patients With Diabetic Nephropathy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "clinicaltrials.gov" "fecha" => "2021" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011500000003/v1_202403090527/S0001731024000243/v1_202403090527/en/main.assets" "Apartado" => array:4 [ "identificador" => "6158" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Revisiones" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000003/v1_202403090527/S0001731024000243/v1_202403090527/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000243?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 19 | 17 | 36 |
2024 October | 178 | 136 | 314 |
2024 September | 181 | 112 | 293 |
2024 August | 271 | 112 | 383 |
2024 July | 324 | 91 | 415 |
2024 June | 219 | 111 | 330 |
2024 May | 278 | 124 | 402 |
2024 April | 237 | 102 | 339 |
2024 March | 431 | 97 | 528 |
2024 February | 171 | 71 | 242 |
2024 January | 404 | 103 | 507 |